SLC1A5 and cancer: Together, our results showed that MLN4924-induced accumulation of ASCT2 appears to be a “side-effect” of the compound, which can be overcome by ASCT2 inhibitor, providing a rational drug combination for maximal therapeutic efficacy in cancer treatment.